肝细胞癌(HCC)是最常见的肝癌类型之一;占病例的75-85%。肝癌的治疗和管理涉及不同的卫生选择,如手术,化疗,免疫疗法,等。最近,在肝肿瘤细胞的诊断和靶向方面已经取得了各种进展。其中,生物标志物被认为是肿瘤细胞诊断和分化的主要来源。随着纳米技术领域的进步,不同类型的纳米载体已经在肿瘤靶向中被证实。纳米载体,如纳米颗粒,脂质体,聚合物胶束,纳米纤维,等。很容易为有效的肿瘤靶向准备,副作用最小。各种方法的出现倾向于提高这些纳米载体的有效性,如在大量临床试验中所证明的。本文综述了甘露糖等碳水化合物的重要作用,半乳糖,果糖,等。在发展中,诊断,和肝癌的治疗。因此,本次审查的当前重点是承认关于发生的各种观点,诊断,治疗,和HCC的管理。
Hepatocellular carcinoma (HCC) is one of the most common types of liver cancer; accounts for 75-85% of cases. The treatment and management of HCC involve different sanative options like surgery, chemotherapy, immunotherapy, etc. Recently, various advancements have been introduced for the diagnosis and targeting of hepatic tumor cells. Among these, biomarkers are considered the primary source for the diagnosis and differentiation of tumor cells. With the advancement in the field of nanotechnology, different types of nanocarriers have been witnessed in tumor targeting. Nanocarriers such as nanoparticles, liposomes, polymeric micelles, nanofibers, etc. are readily prepared for effective tumor targeting with minimal side-effects. The emergence of various approaches tends to improve the effectiveness of these nanocarriers as demonstrated in ample clinical trials. This review focuses on the significant role of carbohydrates such as mannose, galactose, fructose, etc. in the development, diagnosis, and therapy of HCC. Hence, the current focus of this review is to acknowledge various perspectives regarding the occurrence, diagnosis, treatment, and management of HCC.